Dr. Gringeri is a seasoned consultant with over 30 years of experience in leading product development and strategic partnerships. His extensive career includes significant contributions to the fields of biologics and gene therapies. At Amgen, where he spent more than 14 years, Dr. Gringeri held various executive roles, including Vice President of Product Development, Scientific Outreach and Licensing Operations, and Project Management & Strategic Planning. Notably, he was the Product Development Team Leader for Amgen’s blockbuster drug, ARANESP®, which achieved annual sales exceeding $2 billion. His leadership and management skills were instrumental in driving these successes.

​

Following his tenure at Amgen, Dr. Gringeri served as the Chief Operating Officer for Amsterdam Molecular Therapeutics (AMT), a company focused on human gene therapies for orphan diseases. His regulatory expertise and business acumen were further demonstrated in his role as Chief Executive Officer at ImmunoCellular Therapeutics, where he spearheaded the development of dendritic cell-based therapies for brain cancer, leading to promising Phase II clinical trial results. Since 2021, as part of Cell One Partners, Dr. Gringeri has led the development effort at Apriligen, a company developing a stem cell-based gene therapy for a rare pediatric disease, Diamond Blackfan Anemia. Dr. Gringeri's career is marked by his ability to navigate complex regulatory landscapes, drive innovative therapeutic solutions, and achieve significant advancements in the biotechnology industry.